Directly inhibiting Grp94 and clearing a molecular driver of POAG pathology represents a therapeutic strategy distinct from many current glaucoma therapeutics, which attempt to alter either the production or the outflow of aqueous humor1,3. This evidence concerns the gene HSP90B1 and glaucoma.